Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
25.96 (1y: +82%)
Market Cap 377.02 M P/E(ttm) 28.80
Enterprise Value 341.33 M P/B
SRDX- NAS (USA)
SurModics, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$25.96
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry		 vs
history
Cash to Debt No Debt
SRDX's Cash to Debt is ranked higher than
79% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.56 vs. SRDX: No Debt )
SRDX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt
Interest Coverage No Debt
SRDX's Interest Coverage is ranked higher than
96% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. SRDX: No Debt )
SRDX' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 5
Z-Score: 43.6
M-Score: -2.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 33.40
SRDX's Operating margin (%) is ranked higher than
93% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. SRDX: 33.40 )
SRDX' s 10-Year Operating margin (%) Range
Min: -25.8   Max: 51.7
Current: 33.4
-25.8
51.7
Net-margin (%) 21.9
SRDX's Net-margin (%) is ranked higher than
92% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. SRDX: 21.9 )
SRDX' s 10-Year Net-margin (%) Range
Min: -30.2   Max: 32.2
Current: 21.9
-30.2
32.2
Revenue Growth (%) -5.5
SRDX's Revenue Growth (%) is ranked lower than
59% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. SRDX: -5.5 )
SRDX' s 10-Year Revenue Growth (%) Range
Min: -19.1   Max: 45.5
Current: -5.5
-19.1
45.5
ยป SRDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

SRDX Guru Trades in Q2 2012

Joel Greenblatt 44,797 sh (+0.42%)
Chuck Royce 1,055,300 sh (unchged)
PRIMECAP Management Sold Out
Bill Frels 757,295 sh (-0.19%)
Mario Gabelli 195,150 sh (-1.91%)
Jim Simons 72,900 sh (-4.25%)
» More
Q3 2012

SRDX Guru Trades in Q3 2012

Jim Simons 211,038 sh (+189.49%)
Joel Greenblatt 71,768 sh (+60.21%)
Mario Gabelli Sold Out
Bill Frels 756,845 sh (-0.06%)
Chuck Royce 972,800 sh (-7.82%)
» More
Q4 2012

SRDX Guru Trades in Q4 2012

Jim Simons 220,438 sh (+4.45%)
Bill Frels 753,345 sh (-0.46%)
Chuck Royce 921,300 sh (-5.29%)
Joel Greenblatt 53,262 sh (-25.79%)
» More
Q1 2013

SRDX Guru Trades in Q1 2013

Jim Simons 264,200 sh (+19.85%)
Bill Frels 754,340 sh (+0.13%)
Chuck Royce 773,300 sh (-16.06%)
Joel Greenblatt 43,239 sh (-18.82%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2012-12-31 Reduce -25.79%0.03%$17.45 - $22.03 $ 25.9631%53262
Joel Greenblatt 2012-12-31 Reduce -25.79%0.03%$17.45 - $22.03 $ 25.9631%53262
Joel Greenblatt 2012-09-30 Add 60.21%0.04%$15.38 - $20.78 $ 25.9644%71768
Mario Gabelli 2012-09-30 Sold Out 0.03%$15.38 - $20.78 $ 25.9644%0
PRIMECAP Management 2012-06-30 Sold Out 0.0015%$13.6 - $17.22 $ 25.9674%0
Joel Greenblatt 2012-03-31 Add 200.69%0.04%$13.86 - $16.06 $ 25.9689%44610
Joel Greenblatt 2011-12-31 New Buy0.03%$8.86 - $14.99 $ 25.96128%14836
PRIMECAP Management 2011-12-31 Reduce -73.57%$8.86 - $14.99 $ 25.96128%66000
Mario Gabelli 2011-03-31 Add 93.72%$11.53 - $13.18 $ 25.96111%167468
Mario Gabelli 2010-12-31 Add 337.72%$8.33 - $13.11 $ 25.96136%86450
Mario Gabelli 2010-09-30 Add 22.67%$10.67 - $16.5 $ 25.9697%19750
Mario Gabelli 2010-06-30 Reduce -55.56%$16.01 - $22.03 $ 25.9641%16100
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 28.80
SRDX's P/E(ttm) is ranked higher than
60% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.95 vs. SRDX: 28.80 )
SRDX' s 10-Year P/E(ttm) Range
Min: 8.52   Max: 584.75
Current: 28.8
8.52
584.75
P/S 7.54
SRDX's P/S is ranked lower than
80% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. SRDX: 7.54 )
SRDX' s 10-Year P/S Range
Min: 2.16   Max: 61.89
Current: 7.54
2.16
61.89
PFCF 27.30
SRDX's PFCF is ranked lower than
52% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.30 vs. SRDX: 27.30 )
SRDX' s 10-Year PFCF Range
Min: 9.43   Max: 3279
Current: 27.3
9.43
3279
EV-to-EBIT 18.5
SRDX's EV-to-EBIT is ranked higher than
60% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. SRDX: 18.5 )
SRDX' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 474.3
Current: 18.5
4.5
474.3
Shiller P/E 71.4
SRDX's Shiller P/E is ranked higher than
86% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.19 vs. SRDX: 71.4 )
SRDX' s 10-Year Shiller P/E Range
Min: 15.34   Max: 180.45
Current: 71.4
15.34
180.45

Valuation & Return

vs
industry		 vs
history
Price/DCF (Projected) 1.7
SRDX's Price/DCF (Projected) is ranked higher than
84% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. SRDX: 1.7 )
SRDX' s 10-Year Price/DCF (Projected) Range
Min: 0.5   Max: 3.1
Current: 1.7
0.5
3.1
Price/Median PS Value 0.8
SRDX's Price/Median PS Value is ranked higher than
62% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. SRDX: 0.8 )
SRDX' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 3.4
Current: 0.8
0.2
3.4
Earnings Yield (Greenblatt) 5.40
SRDX's Earnings Yield (Greenblatt) is ranked higher than
68% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. SRDX: 5.40 )
SRDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 22
Current: 5.4
0.2
22
Forward Rate of Return (Yacktman) 2.78
SRDX's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. SRDX: 2.78 )
SRDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.7   Max: 59.7
Current: 2.78
0.7
59.7

Business Description

SurModics, Inc. is a Minnesota Corporation. The Company is a provider of drug delivery and surface modification technologies to the healthcare industry. The Company's core offerings include: drug delivery technologies (coatings, microparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility characteristics; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. It partners with many of the emerging medical device, pharmaceutical and life science companies to develop and commercialize innovative products designed to improve patient outcomes. In the product lines in which The Company competes (protein stabilization reagents, substrates, recombinant autoimmune antigens and surface chemistry technologies), it faces an array of competitors ranging from large manufacturers with multiple business lines to small manufacturers that offer a limited selection of products. Although its drug delivery and surface modification technologies themselves are not directly regulated by the Food and Drug Administration (FDA), the medical devices, pharmaceutical and biotechnology products incorporating its technologies are subject to FDA regulation.
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ
ยป More Articles for SRDX

Headlines

Articles On GuruFocus.com
Mairs & Power Funds Buys Hormel Buys HRL, MDT, PG, DIS, WAG, NVEC, IWR, SCHB, Sells SSYS, SRDX, ADP, Feb 17 2011 
SurModics Inc. Reports Operating Results (10-Q) Aug 06 2010 
SurModics Inc. Reports Operating Results (10-Q) May 07 2010 
SurModics Inc. Reports Operating Results (10-Q) Feb 05 2010 
SurModics Inc. Reports Operating Results (10-K) Dec 11 2009 
SurModics Inc. (SRDX) Senior VP & CFO Philip D Ankeny sells 5,000 Shares Oct 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Aug 07 2009 
SurModics Inc. Reports Operating Results (10-Q) May 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Feb 09 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial